SCHEMBL6782609

SCHEMBL6782609

Cc1ccc(S(=O)(=O)c2ccc(C)c(Br)c2)cc1Br

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
POLB P06746 2/20 0.48
MAPT P10636 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
GAA P10253 3/20 0.46
LMNA P02545 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
CA2 P00918 3/20 0.42
TSHR P16473 2/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA6 P23280 2/20 0.42
CA5A P35218 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA5B Q9Y2D0 2/20 0.42
MAPK1 P28482 1/20 0.42
CA4 P22748 1/20 0.42
CA14 Q9ULX7 1/20 0.42
RAPGEF4 Q8WZA2 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8471385 0.90 ALDH1A1 (0.64) ALDH1A1POLBMAPTSMN1; SMN2GAA
SCHEMBL1368195 0.84 CA2 (0.61) POLBMAPTLMNACA2CA12
SCHEMBL30098266 0.84 PTGS2 (0.42) ALDH1A1SMN1; SMN2LMNATDP1CA2
SCHEMBL2586501 0.84 PTGS2 (0.42) ALDH1A1SMN1; SMN2LMNATDP1CA2
SCHEMBL31402607 0.84 LMNA (0.42) ALDH1A1POLBMAPTSMN1; SMN2GAA
SCHEMBL31689531 0.83 LMNA (0.41) ALDH1A1POLBMAPTSMN1; SMN2LMNA
SCHEMBL7546641 0.83 LMNA (0.41) ALDH1A1POLBMAPTSMN1; SMN2LMNA
SCHEMBL11353339 0.83 LMNA (0.41) ALDH1A1MAPTSMN1; SMN2LMNATDP1
SCHEMBL6995604 0.83 ALDH1A1 (0.42) ALDH1A1MAPTSMN1; SMN2GAALMNA
SCHEMBL5524384 0.82 ALDH1A1 (0.50) ALDH1A1POLBMAPTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed
US-4046656-A Photochlorination process for methyl aromatic compounds THE DOW CHEMICAL COMPANY (US) 1977-09-06 US disclosed